Clinical radioimmunotherapy-the role of radiobiology - Université Toulouse III - Paul Sabatier - Toulouse INP Accéder directement au contenu
Article Dans Une Revue Nature Reviews Clinical Oncology Année : 2011

Clinical radioimmunotherapy-the role of radiobiology

Résumé

Conventional external-beam radiation therapy is dedicated to the treatment of localized disease, whereas radioimmunotherapy represents an innovative tool for the treatment of local or diffuse tumors. Radioimmunotherapy involves the administration of radiolabeled monoclonal antibodies that are directed specifically against tumor-associated antigens or against the tumor microenvironment. Although many tumor-associated antigens have been identified as possible targets for radioimmunotherapy of patients with hematological or solid tumors, clinical success has so far been achieved mostly with radiolabeled antibodies against CD20 ( 131I-tositumomab and 90 Y-ibritumomab tiuxetan) for the treatment of lymphoma. In this Review, we provide an update on the current challenges aimed to improve the efficacy of radioimmunotherapy and discuss the main radiobiological issues associated with clinical radioimmunotherapy. © 2011 Macmillan Publishers Limited. All rights reserved.
Fichier non déposé

Dates et versions

hal-02962928 , version 1 (09-10-2020)

Identifiants

Citer

J.-P. Pouget, I. Navarro-Teulon, M. Bardiès, N. Chouin, G. Cartron, et al.. Clinical radioimmunotherapy-the role of radiobiology. Nature Reviews Clinical Oncology, 2011, 8 (12), pp.720--734. ⟨10.1038/nrclinonc.2011.160⟩. ⟨hal-02962928⟩
37 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More